On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends ...

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H ...

With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007 ...

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...

The first industry-designed accreditation dedicated specifically to the safe, compliant, and human-supervised use of AI ...

Students also visited the CDFD Technology Incubator for live interactions with incubated startups, gaining practical insights into turning ideas into viable businesses.

New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug ...

When Hurricane Helene tore through Western North Carolina in September 2024, it didn't just uproot trees and wash out roads.